Cytosorbents Corporation (CTSO) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CTSO Revenue Growth
Revenue Breakdown (FY 2023)
CTSO's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
By Geography
CTSO Revenue Analysis (2013–2024)
As of May 8, 2026, Cytosorbents Corporation (CTSO) generated trailing twelve-month (TTM) revenue of $36.1 million, reflecting solid growth of +8.8% year-over-year. The most recent quarter (Q2 2025) recorded $9.6 million in revenue, up 10.2% sequentially.
Looking at the longer-term picture, CTSO's 5-year compound annual growth rate (CAGR) stands at +9.4%, indicating steady revenue expansion. The company achieved its highest annual revenue of $40.1 million in 2021.
Revenue diversification analysis shows CTSO's business is primarily driven by Grant income (99%), and Other sales (1%). With over half of revenue concentrated in Grant income, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVCR (+8.5% YoY), MASI (-14.4% YoY), and ICUI (-10.9% YoY), CTSO has underperformed the peer group in terms of revenue growth. Compare CTSO vs NVCR →
CTSO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CTSOCurrent | $36M | +8.8% | +9.4% | -47.2% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 MASI | $1.5B | -14.4% | +5.9% | 20.5% | |
 ICUI | $2.2B | -10.9% | +11.9% | 4.8% | |
 LMAT | $250M | +13.3% | +14.0% | 27.2% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% |
CTSO Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $35.6M | +14.5% | $25.1M | 70.6% | $-16,785,939 | -47.2% |
| 2023 | $31.1M | -10.4% | $22.0M | 70.6% | $-31,948,620 | -102.8% |
| 2022 | $34.7M | -13.5% | $20.7M | 59.8% | $-31,521,879 | -90.9% |
| 2021 | $40.1M | +1.7% | $29.1M | 72.5% | $-22,744,745 | -56.7% |
| 2020 | $39.5M | +73.3% | $28.4M | 72.0% | $-10,370,334 | -26.3% |
| 2019 | $22.8M | +12.4% | $15.4M | 67.7% | $-18,974,000 | -83.3% |
| 2018 | $20.3M | +51.3% | $12.8M | 63.0% | $-15,584,928 | -77.0% |
| 2017 | $13.4M | +63.1% | $7.9M | 58.8% | $-9,842,598 | -73.6% |
| 2016 | $8.2M | +102.3% | $4.3M | 51.8% | $-11,492,125 | -140.0% |
| 2015 | $4.1M | +29.0% | $1.8M | 45.4% | $-9,303,659 | -229.4% |
See CTSO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTSO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTSO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTSO — Frequently Asked Questions
Quick answers to the most common questions about buying CTSO stock.
Is CTSO's revenue growth accelerating or slowing?
CTSO maintains +8.8% revenue growth, in line with its 5-year CAGR of +9.4%. TTM revenue stands at $36M. Growth rate remains consistent with historical average.
What is CTSO's long-term revenue growth rate?
Cytosorbents Corporation's 5-year revenue CAGR of +9.4% reflects the sustained expansion pattern. Current YoY growth of +8.8% is near this long-term average.
How is CTSO's revenue distributed by segment?
CTSO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.